{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:39:01Z","timestamp":1771515541142,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03280-8","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T14:02:21Z","timestamp":1656856941000},"page":"2167-2174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravesical sustained release system of lidocaine and oxybutynin results from in vitro and animal study"],"prefix":"10.1007","volume":"54","author":[{"given":"David","family":"Dothan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galiya","family":"Raisin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Malchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Touitou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-0969","authenticated-orcid":false,"given":"Boris","family":"Chertin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"key":"3280_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/s0022-5347(05)67551-9","volume":"163","author":"GA Barbalias","year":"2000","unstructured":"Barbalias GA, Liatsikos EN, Nikiforidis G (2000) Interstitial cystitis: Bladder training with intravesical Oxybutynin. J Urol 163:1818\u20131822. https:\/\/doi.org\/10.1016\/s0022-5347(05)67551-9","journal-title":"J Urol"},{"key":"3280_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1464-410X.2008.08162.x","volume":"103","author":"JC Nickel","year":"2009","unstructured":"Nickel JC, Moldwin R, Lee S et al (2009) Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int 103:910\u2013918. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08162.x","journal-title":"BJU Int"},{"key":"3280_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.urology.2015.01.021","volume":"85","author":"RA Henry","year":"2015","unstructured":"Henry RA, Morales A, Cahill CM (2015) Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis\/bladder pain syndrome. Urology 85:1025\u20131033. https:\/\/doi.org\/10.1016\/j.urology.2015.01.021","journal-title":"Urology"},{"key":"3280_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ucl.2006.06.012","volume":"33","author":"P Tyagi","year":"2006","unstructured":"Tyagi P, Tyagi S, Kaufman J et al (2006) Local drug delivery to bladder using technology innovations. Urol Clin North Am 33:519\u2013530. https:\/\/doi.org\/10.1016\/j.ucl.2006.06.012","journal-title":"Urol Clin North Am"},{"key":"3280_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/00003081-200312000-00011","volume":"46","author":"WB Charles","year":"2003","unstructured":"Charles WB (2003) Interstitial cystitis and chronic pelvic pain: new insights in neuropathology, diagnosis, and treatment. Clin Obstet Gynecol 46:811\u2013823. https:\/\/doi.org\/10.1097\/00003081-200312000-00011","journal-title":"Clin Obstet Gynecol"},{"key":"3280_CR6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno PM, Erickson D, Moldwin R, Faraday MM (2015) Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J Urol 193:1545\u20131553. https:\/\/doi.org\/10.1016\/j.juro.2015.01.086","journal-title":"J Urol"},{"key":"3280_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2009.08.020","volume":"57","author":"M Fall","year":"2010","unstructured":"Fall M, Baranowski AP, Elneil S et al (2010) EAU Guidelines on chronic pelvic pain. Eur Urol 57:35\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2009.08.020","journal-title":"Eur Urol"},{"key":"3280_CR8","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00192-019-03970-5","volume":"30","author":"J Pape","year":"2019","unstructured":"Pape J, Falconi G, De Mattos Lourenco TR et al (2019) Variations in bladder pain syndrome\/interstitial cystitis (IC) definitions, pathogenesis, diagnostics and treatment: a systematic review and evaluation of national and international guidelines. Int Urogynecol J 30:1795\u20131805. https:\/\/doi.org\/10.1007\/s00192-019-03970-5","journal-title":"Int Urogynecol J"},{"key":"3280_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1023\/A:1017595401988","volume":"32","author":"A Ersay","year":"2001","unstructured":"Ersay A, Demirtas OC (2001) Intravesical oxybutynin affects bladder permeability. Int Urol Nephrol 32:359\u2013361. https:\/\/doi.org\/10.1023\/A:1017595401988","journal-title":"Int Urol Nephrol"},{"key":"3280_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S0022-5347(01)65238-8","volume":"157","author":"LS Palmer","year":"1997","unstructured":"Palmer LS, Zebold K, Firlit CF, Kaplan WE (1997) Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 157:638\u2013640. https:\/\/doi.org\/10.1016\/S0022-5347(01)65238-8","journal-title":"J Urol"},{"key":"3280_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","volume":"50","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Di Stasi SM, Chancellor MB et al (2006) New frontiers in intravesical therapies and drug delivery. Eur Urol 50:1183\u20131193. https:\/\/doi.org\/10.1016\/j.eururo.2006.08.025","journal-title":"Eur Urol"},{"key":"3280_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1046\/j.1464-410x.2001.02227.x","volume":"87","author":"G Lose","year":"2001","unstructured":"Lose G, N\u00f8rgaard JP (2001) Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int 87:767\u2013773. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02227.x","journal-title":"BJU Int"},{"key":"3280_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1445-2197.1997.tb07119.x","volume":"67","author":"AJA Holland","year":"1997","unstructured":"Holland AJA, King PA, Chauvel PJ et al (1997) Intravesical therapy for the treatment of neurogenic bladder in children. ANZ J Surg 67:731\u2013733. https:\/\/doi.org\/10.1111\/j.1445-2197.1997.tb07119.x","journal-title":"ANZ J Surg"},{"key":"3280_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12894-019-0495-z","volume":"19","author":"D Leonh\u00e4user","year":"2019","unstructured":"Leonh\u00e4user D, Kranz J, Leidolf R et al (2019) Expression of components of the urothelial cholinergic system in bladder and cultivated primary urothelial cells of the pig. BMC Urol 19:62. https:\/\/doi.org\/10.1186\/s12894-019-0495-z","journal-title":"BMC Urol"},{"key":"3280_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","volume":"157","author":"K Waldeck","year":"1997","unstructured":"Waldeck K, Larsson B, Andersson K-E (1997) Comparison of oxybutynin and its active metabolite, N-Desethyl-Oxybutynin, in the human detrusor and parotid Gland. J Urol 157:1093\u20131097. https:\/\/doi.org\/10.1016\/S0022-5347(01)65148-6","journal-title":"J Urol"},{"key":"3280_CR16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0022-5347(05)65540-1","volume":"166","author":"SMD Stasi","year":"2001","unstructured":"Stasi SMD, Giannantoni A, Navarra P et al (2001) Intravesical Oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of Oxybutynin and N-Desethyl Oxybutynin. J Urol 166:2232\u20132236. https:\/\/doi.org\/10.1016\/S0022-5347(05)65540-1","journal-title":"J Urol"},{"key":"3280_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0378-4347(99)00326-6","volume":"734","author":"R Massoud","year":"1999","unstructured":"Massoud R, Federici G, Casciani S et al (1999) Extraction and determination of oxybutynin in human bladder samples by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 734:163\u2013167. https:\/\/doi.org\/10.1016\/S0378-4347(99)00326-6","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"3280_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/S0022-5347(17)41304-8","volume":"141","author":"CB Brendler","year":"1989","unstructured":"Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141:1350\u20131352. https:\/\/doi.org\/10.1016\/S0022-5347(17)41304-8","journal-title":"J Urol"},{"key":"3280_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0090-4295(93)90098-U","volume":"41","author":"DL Weese","year":"1993","unstructured":"Weese DL, Roskamp DA, Leach GE, Zimmern PE (1993) Intravesical oxybutynin chloride: experience with 42 patients. Urology 41:527\u2013530. https:\/\/doi.org\/10.1016\/0090-4295(93)90098-U","journal-title":"Urology"},{"key":"3280_CR20","first-page":"143","volume":"4","author":"Michael Cima JCN","year":"2012","unstructured":"Michael Cima JCN (2012) Continuous intravesical lidocaine treatment for interstitial cystitis\/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med 4:143","journal-title":"Sci Transl Med"},{"key":"3280_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0022-5347(17)36663-6","volume":"148","author":"FE Trigo-Rocha","year":"1992","unstructured":"Trigo-Rocha FE, CAM, (1992) The pharmacokinetics of intravesical and oral oxybutynin chloride. Sci.Direct 148:595\u2013597. https:\/\/doi.org\/10.1016\/S0022-5347(17)36663-6","journal-title":"Sci.Direct"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03280-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03280-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:38:26Z","timestamp":1660214306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03280-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3280"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03280-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Dothan, Galiya Raisin and Boris Chertin\u2014None of the authors has a conflict of interest to declare. Nadav Malchi, Avi Gordon, Dan Touitou are employers of TRIGON Pharma, which developed TRG-042.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}